coBRIM研究中维莫非尼联合考比替尼相关毒性的发生率、病程与管理
coBRIM III期试验中,维莫非尼联合考比替尼较维莫非尼单药显著改善晚期BRAF突变黑色素瘤的无进展生存(HR 0.58,P<0.0001)和总生存(HR 0.70,P=0.005)。本文报告该研究关键不良事件的发生率、病程与管理,联合组3级及以上不良事件频率高于单药组(75%对61%),多数不良事件发生在首个治疗周期内,经支持治疗、剂量调整和监测可管理。
要点
- 联合组3级及以上不良事件频率75%,单药组61%。
- 多数不良事件(含3级及以上)发生在首个治疗周期内。
- 首个周期后常见不良事件发生率随时间显著下降。
核心结论
- 考比替尼联合维莫非尼相关不良事件多发生于治疗早期,多为轻至中度,通过患者监测、剂量调整和支持治疗可管理。
研究设计与样本
- coBRIM III期试验,患者1:1随机接受维莫非尼(960 mg每日两次)联合考比替尼(60 mg每日一次,用21天停7天)或安慰剂。
- 安全性人群493例(联合组247例,维莫非尼单药组246例),截至2015年9月30日数据截断时中位随访18.5个月。
- 除标准安全性评估外,患者定期接受眼科、心脏和皮肤科监测检查。
主要发现
- 联合组3级及以上不良事件频率75%,维莫非尼单药组61%。
- 多数不良事件(包括3级及以上)发生在首个治疗周期内。
- 首个周期(28天)后,常见不良事件(皮疹、腹泻、光敏反应、肌酸磷酸激酶升高、浆液性视网膜病变、发热和肝脏实验室异常)的发生率随时间显著下降。
- 多数不良事件通过支持治疗、研究治疗剂量调整以及偶见的永久停药进行保守管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study. PATIENTS AND METHODS: Patients were randomly assigned 1:1 to receive vemurafenib (960 mg twice a day) and either cobimetinib (60 mg once a day, 21 days on/7 days off) or placebo. In addition to standard safety evaluations, patients underwent regular ophthalmic, cardiac, and dermatologic surveillance examinations. RESULTS: Of 495 patients recruited to the study, 493 patients received treatment and constituted the safety population (cobimetinib combined with vemurafenib, 247; vemurafenib, 246). At data cut-off (30 September 2015), median follow-up was 18.5 months. Nearly every patient experienced an AE. In patients who received cobimetinib combined with vemurafenib, the frequency of grade ≥3 AEs was higher than in patients who received vemurafenib alone (75% versus 61%). Most AEs, including grade ≥3 AEs, occurred within the first treatment cycle. After the first cycle (28 days), the incidence of common AEs (rash, diarrhoea, photosensitivity, elevated creatine phosphokinase, serous retinopathy, pyrexia, and liver laboratory abnormalities) decreased substantially over time. Most AEs were managed conservatively by supportive care measures, dose modifications of study treatment, and, occasionally, permanent treatment discontinuation. CONCLUSIONS: These data indicate that most AEs arising from treatment with cobimetinib combined with vemurafenib generally occur early in the treatment course, are mild or moderate and are manageable by patient monitoring, dose modification and supportive care. CLINICALTRIALS.GOV: NCT01689519.
引用
- Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017. PMID: 28444112. doi:10.1093/annonc/mdx040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。